Neurosense Therapeutics Ltd Total Assets
Neurosense Therapeutics Ltd total assets. Based on the latest financial reports, Neurosense Therapeutics Ltd (NRSN) holds total assets worth $1.03 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Neurosense Therapeutics Ltd stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Neurosense Therapeutics Ltd (2019–2025)
Total assets of Neurosense Therapeutics Ltd from 2019 to 2025. This chart illustrates how Neurosense Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data. See Neurosense Therapeutics Ltd (NRSN) share price today for real-time trading data and today's change.
Neurosense Therapeutics Ltd - Asset Composition Analysis
Neurosense Therapeutics Ltd Total Assets Breakdown (December 2025)
Neurosense Therapeutics Ltd total assets breakdown as of December 2025. Neurosense Therapeutics Ltd's total assets of $1.03 Million consist of 75.7% current assets and 24.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.2% |
| Accounts Receivable | $33.00K | 3.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Neurosense Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore NRSN working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neurosense Therapeutics Ltd's current assets represent 75.7% of total assets in 2025, a decrease from 95.6% in 2019.
- Cash Position: Cash and equivalents constituted 16.2% of total assets in 2025, down from 93.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 3.2% of total assets.
Neurosense Therapeutics Ltd Competitors by Total Assets
Key competitors of Neurosense Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Genmab A/S
CO:GMAB
|
Denmark | Dkr7.02 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $521.90 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
Neurosense Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.31 | 2.21 | 17.48 |
| Quick Ratio | 0.31 | 2.21 | 17.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.74 Million | $2.41 Million | $659.00K |
Neurosense Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Neurosense Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.64 |
| Latest Market Cap to Assets Ratio | 14.73 |
| Asset Growth Rate (YoY) | -77.5% |
| Total Assets | $1.03 Million |
| Market Capitalization | $15.14 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Neurosense Therapeutics Ltd's assets at a significant premium (14.73x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Neurosense Therapeutics Ltd's assets decreased by 77.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Neurosense Therapeutics Ltd (2019–2025)
The table below shows the annual total assets of Neurosense Therapeutics Ltd from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.03 Million | -77.53% |
| 2024-12-31 | $4.58 Million | +43.64% |
| 2023-12-31 | $3.19 Million | -58.69% |
| 2022-12-31 | $7.71 Million | -32.55% |
| 2021-12-31 | $11.43 Million | +1367.39% |
| 2020-12-31 | $779.00K | -18.43% |
| 2019-12-31 | $955.00K | -- |
About Neurosense Therapeutics Ltd
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for t… Read more